Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
Status:
RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of butylphthalide soft capsules for treating cognitive impairment in elderly patients with focal epilepsy.
Study Population: 220 elderly patients (60-85 years) with focal epilepsy and mild to moderate cognitive impairment (Montreal Cognitive Assessment score 18-25).
Intervention: Participants will be randomly assigned 1:1 to receive either butylphthalide soft capsules (0.2g three times daily) or matching placebo for 48 weeks, while continuing their stable anti-seizure medication regimen.
Primary Outcome: Change in Montreal Cognitive Assessment (MoCA) total score from baseline to 48 weeks.
Secondary Outcomes: Changes in neuropsychological tests (Trail Making Test, Digit Span, Rey Auditory Verbal Learning Test), seizure control measures, functional status (Activities of Daily Living, Quality of Life in Epilepsy), and exploratory neurobiological markers.
This study addresses an important unmet medical need, as current epilepsy treatments focus primarily on seizure control but lack effective interventions for epilepsy-associated cognitive impairment. Butylphthalide, a neuroprotective agent approved for acute ischemic stroke in China, has shown promise in other cognitive disorders and may benefit this patient population through its multiple neuroprotective mechanisms.
Phase:
PHASE4
Details
Lead Sponsor:
First Affiliated Hospital of Wenzhou Medical University
Collaborators:
Affiliated Yueqing Hospital of Wenzhou Medical University Lishui Country People's Hospital Taizhou Central Hospital affiliated to Taizhou University The Third Affiliated Hospital of Wenzhou Medical University